ERAS
Erasca, Inc. Health Care Pharmaceutical Preparations Russell 3000
$14.35Close
$4.1BMarket cap
$2.20 – $22.4752-week range
Nov 11, 2026Next report
Highlights
Strengths
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 36% below its 52-week high
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
36%
1wk
down 0.3%
price change
1mo
down 2.1%
price change
12-month return
up 483%
market up 11% ·
its own up 497%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
12.5×
price / book
Earnings yield
down 3.5%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 33%
return on equity
Free cash margin
—
-$95.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.8%
$0.97 a day · 2×ATR $12.41
RS
99 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.90
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+3% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$109.3M | -$124.9M | -$247.4M | -$141.5M | -$179.6M | -$140.9M |
| Net income | -$101.7M | -$122.8M | -$242.8M | -$125.0M | -$161.7M | -$124.5M |
| Earnings per share | — | -$1.85 | -$1.99 | -$0.83 | -$0.69 | -$0.44 |
| Free cash flow | -$33.6M | -$90.8M | -$117.8M | -$103.0M | -$109.5M | -$95.6M |
| Cash | $65.4M | $360.5M | $284.2M | $93.1M | $67.7M | $73.8M |
| Shareholders' equity | -$114.0M | $456.5M | $411.9M | $316.7M | $423.5M | $325.2M |
| Shares outstanding | 26.31m | 119.10m | 149.33m | 151.09m | 283.22m | 284.16m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 16, 2026 | Director or officer change ↗ |
| Aug 24, 2026 | Other events ↗ |
| Aug 11, 2026 | Results ↗ |
| Aug 10, 2026 | Director or officer change ↗ |
| Jul 14, 2026 | Other events ↗ |
| Jul 13, 2026 | Other events ↗ |
| Jul 1, 2026 | Shareholder vote ↗ |
| May 11, 2026 | Results ↗ |
| Apr 27, 2026 | Other events ↗ |
| Apr 27, 2026 | Regulation FD · Other events ↗ |
| Apr 21, 2026 | Other events ↗ |
| Mar 12, 2026 | Results ↗ |